Deciphera Pharmaceuticals Current Ratio 2016-2021 | DCPH

Deciphera Pharmaceuticals current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Deciphera Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.44B $0.07B 6.62
2021-03-31 $0.55B $0.06B 8.57
2020-12-31 $0.58B $0.07B 8.34
2020-09-30 $0.57B $0.06B 9.34
2020-06-30 $0.63B $0.05B 12.33
2020-03-31 $0.70B $0.05B 15.61
2019-12-31 $0.59B $0.06B 9.88
2019-09-30 $0.64B $0.04B 15.20
2019-06-30 $0.26B $0.04B 7.26
2019-03-31 $0.27B $0.03B 9.55
2018-12-31 $0.30B $0.02B 13.24
2018-09-30 $0.33B $0.02B 18.45
2018-06-30 $0.35B $0.02B 18.44
2018-03-31 $0.18B $0.02B 11.12
2017-12-31 $0.20B $0.01B 14.35
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.06B $0.01B 12.78
2015-12-31 $0.03B $0.00B 8.65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.967B $0.042B
Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86